See more : Selectirente (SELER.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Outlook Therapeutics, Inc. (OTLK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Outlook Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sino AG (XTP.DE) Income Statement Analysis – Financial Results
- EBR Systems, Inc. (EBR.AX) Income Statement Analysis – Financial Results
- PT. Prima Alloy Steel Universal Tbk. (PRAS.JK) Income Statement Analysis – Financial Results
- ZignSec AB (publ) (ZIGN.ST) Income Statement Analysis – Financial Results
- Catalyst Partners Acquisition Corp. (CPARW) Income Statement Analysis – Financial Results
Outlook Therapeutics, Inc. (OTLK)
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.15M | 3.09M | 3.81M | 2.98M | 5.22M | 9.05M |
| Cost of Revenue | 0.00 | 44.19K | 204.69K | 262.14K | 554.07K | 23.81K | 18.50K | 23.81K | 32.76K | 38.88K | 14.12K |
| Gross Profit | 0.00 | -44.19K | -204.69K | -262.14K | -554.07K | 8.12M | 3.07M | 3.79M | 2.95M | 5.18M | 9.04M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 99.71% | 99.40% | 99.38% | 98.90% | 99.26% | 99.84% |
| Research & Development | 41,763.05B | 26.45M | 42.33M | 38.96M | 26.34M | 23.81M | 18.50M | 23.81M | 32.76M | 38.88M | 14.12M |
| General & Administrative | 29,940.19B | 26.67M | 20.74M | 12.77M | 9.97M | 9.37M | 14.23M | 15.88M | 21.64M | 12.91M | 7.32M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 279.68K | -1.90M | -3.85M | -7.25M | -2.69M | -2.47M | 0.00 | 0.00 |
| SG&A | 29,940.19B | 26.67M | 20.74M | 13.05M | 8.08M | 5.52M | 6.97M | 13.19M | 19.17M | 12.91M | 7.32M |
| Other Expenses | 0.00 | 0.00 | -882.90K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 71,703.24B | 53.13M | 63.07M | 51.73M | 36.31M | 29.33M | 25.48M | 39.69M | 51.93M | 51.78M | 21.44M |
| Cost & Expenses | 0.00 | 53.13M | 63.07M | 51.73M | 36.31M | 32.69M | 28.53M | 39.69M | 54.74M | 51.78M | 21.44M |
| Interest Income | -906.15B | 1.56K | 1.49K | 936.13 | 1.76K | 3.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3,156.96B | 1.56M | 1.49M | 936.00K | 1.76M | 3.47M | 3.89M | 5.63M | 1.47M | 2.30M | 901.05K |
| Depreciation & Amortization | 0.00 | 44.19K | 204.69K | 262.14K | 554.07K | 3.36M | 3.05M | 2.69M | 2.39M | 1.82M | 878.48K |
| EBITDA | -71,703.24B | -57.38M | -62.87M | -51.46M | -35.76M | -31.11M | -26.79M | -30.03M | -48.95M | -44.74M | -11.51M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -265.98% | -725.17% | -870.73% | -1,656.75% | -857.18% | -127.22% |
| Operating Income | -71,703.24B | -53.13M | -63.07M | -51.73M | -36.84M | -36.30M | -25.44M | -35.88M | -51.76M | -46.56M | -12.39M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -445.60% | -824.09% | -941.36% | -1,737.10% | -892.13% | -136.92% |
| Total Other Income/Expenses | -3,660.68B | -5.85M | -2.98M | -1.43M | -1.67M | -1.64M | -4.10M | -2.47M | -1.85M | -2.30M | -901.05K |
| Income Before Tax | -75,363.91B | -58.98M | -66.05M | -53.16M | -38.51M | -37.93M | -33.74M | -38.35M | -53.23M | -48.86M | -13.29M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -465.68% | -1,092.78% | -1,006.10% | -1,786.37% | -936.15% | -146.88% |
| Income Tax Expense | 2.80B | 2.80K | 2.80K | 2.00K | -3.27M | -3.41M | -3.65M | 501.50K | 103.00K | -190.11K | 439.02K |
| Net Income | -75,366.71B | -58.98M | -66.05M | -53.16M | -35.24M | -34.52M | -46.11M | -38.85M | -53.33M | -47.39M | -13.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -423.81% | -1,493.57% | -1,019.26% | -1,789.83% | -908.05% | -151.73% |
| EPS | -4.06K | -4.72 | -6.23 | -6.96 | -9.71 | -37.96 | -50.70 | -258.75 | -495.71 | -504.47 | -155.35 |
| EPS Diluted | -4.06K | -4.72 | -6.23 | -6.96 | -9.71 | -37.96 | -50.70 | -258.54 | -495.71 | -504.47 | -155.35 |
| Weighted Avg Shares Out | 18.55B | 12.51M | 10.60M | 7.63M | 3.63M | 909.59K | 909.59K | 150.14K | 107.58K | 93.95K | 88.40K |
| Weighted Avg Shares Out (Dil) | 18.55B | 12.51M | 10.60M | 7.63M | 3.63M | 909.59K | 909.59K | 150.26K | 107.58K | 93.95K | 88.40K |
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010
ISELIN, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that, following receipt of...
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Dec. 19, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OTLK
NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK) and certain officers. The class action, filed in the United States...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Outlook Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: OTLK)
NEW YORK , Dec. 18, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Outlook Therapeutics, Inc.. Shareholders who purchased shares of OTLK during the class period listed are encouraged to contact the firm regarding...
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
NEW YORK , Dec. 17, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December 29, 2022 and August 29, 2023, both dates inclusive (the "Class...
OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit
LOS ANGELES , Dec. 15, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK).
OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit
LOS ANGELES , Dec. 14, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK)....
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Dec. 12, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf...
ROSEN, A RANKED AND LEADING FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
NEW YORK , Dec. 11, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December 29, 2022 and August 29, 2023, both dates inclusive (the "Class...
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Outlook Therapeutics, Inc. ("Outlook" or "the Company") (NASDAQ:OTLK) for violations of §§10(b)...
Source: https://incomestatements.info
Category: Stock Reports